2018 tables: Institutions - biological sciences - corporate

The 2018 tables are based on Nature Index data from 1 January 2017 to 31 December 2017.

Table criteria

# Institution Share 2016 Share 2017 Count 2017 Change in Adjusted Share* 2016–2017
1 Merck & Co., Inc., United States of America (USA) 7.06 13.07 41 80.2%
2 Amgen Inc., United States of America (USA) 13.48 11.72 50 -15.5%
3 Pfizer Inc., United States of America (USA) 15.22 11.03 44 -29.5%
4 Johnson & Johnson, United States of America (USA) 5.15 5.62 28 6.1%
5 AbbVie Inc., United States of America (USA) 0.20 5.59 16 2607.2%
6 Bristol-Myers Squibb (BMS), United States of America (USA) 4.17 5.03 21 17.5%
7 Regeneron Pharmaceuticals, Inc., United States of America (USA) 4.57 4.95 16 5.3%
8 Alphabet Inc., United States of America (USA) 3.87 4.48 14 12.5%
9 Biogen Inc., United States of America (USA) 2.74 4.41 16 56.2%
10 IBM Corporation, United States of America (USA) 0.43 4.09 17 826.0%
11 Human Longevity, Inc., United States of America (USA) 0.99 3.74 8 267.8%
12 New England Biolabs, Inc. (NEB), United States of America (USA) 1.57 3.63 8 125.3%
13 Eli Lilly and Company, United States of America (USA) 7.98 3.63 15 -55.8%
14 Ionis Pharmaceuticals, Inc., United States of America (USA) 3.58 3.45 18 -6.2%
15 Leidos Holdings, Inc., United States of America (USA) 4.98 3.44 54 -32.8%
16 Illumina, Inc., United States of America (USA) 2.71 3.18 13 14.1%
17 NGM Biopharmaceuticals, Inc., United States of America (USA) 0.64 2.54 3 284.3%
18 Synthetic Genomics, Inc. (SGI), United States of America (USA) 1.40 2.30 3 60.1%
19 Foundation Medicine, Inc., United States of America (USA) 1.04 2.27 4 111.7%
20 10x Genomics, United States of America (USA) 1.12 2.01 4 73.8%
21 DowDuPont Inc., United States of America (USA) 4.64 1.89 10 -60.4%
22 Thermo Fisher Scientific Inc., United States of America (USA) 1.62 1.75 11 5.2%
23 Adaptive Biotechnologies LLC, United States of America (USA) 0.32 1.75 8 436.2%
24 SomaLogic, Inc., United States of America (USA) 0.05 1.68 3 3501.2%
25 Gilead Sciences, Inc., United States of America (USA) 1.94 1.64 3 -17.9%
26 23andMe, Inc., United States of America (USA) 1.82 1.55 12 -16.9%
27 Oncomed Pharmaceuticals, Inc., United States of America (USA) 1.17 1.40 2 16.7%
28 Microsoft Corporation, United States of America (USA) 1.28 1.38 7 4.9%
29 HRL Laboratories LLC, United States of America (USA) 1.13 2 N/A
30 Adimab LLC, United States of America (USA) 0.20 1.09 2 430.4%
31 Editas Medicine, Inc., United States of America (USA) 0.20 1.00 1 386.2%
31 Immunomedics, Inc., United States of America (USA) 1.00 1 N/A
31 BioMarin Pharmaceutical, Inc., United States of America (USA) 1.00 1 N/A
32 GeneDx Inc., United States of America (USA) 1.80 0.96 14 -47.9%
33 Wave Life Sciences Ltd., United States of America (USA) 0.95 1 N/A
34 Pacific Biosciences of California, Inc., United States of America (USA) 1.65 0.88 6 -48.4%
35 Ancestry.com, Inc., United States of America (USA) 0.04 0.84 1 2029.1%
36 Merrimack Pharmaceuticals, Inc., United States of America (USA) 1.21 0.81 1 -34.9%
37 Caribou Biosciences, Inc., United States of America (USA) 0.71 0.81 1 10.2%
38 Blueprint Medicines, United States of America (USA) 0.81 1 N/A
39 Translate Bio, Inc., United States of America (USA) 0.78 1 N/A
40 Everon Biosciences, Inc., United States of America (USA) 0.75 1 N/A
41 Sanaria Inc., United States of America (USA) 0.23 0.74 2 209.8%
42 Vir Biotechnology, Inc., United States of America (USA) 0.65 0.72 3 8.9%
43 Epic Sciences Inc., United States of America (USA) 0.67 1 N/A
44 Ironwood Pharmaceuticals, Inc., United States of America (USA) 0.64 1 N/A
45 Cell Signaling Technology, Inc., United States of America (USA) 0.08 0.63 6 638.6%
46 Inter-American Development Bank (IDB), United States of America (USA) 0.63 2 N/A
47 Arcturus Therapeutics, Inc., United States of America (USA) 0.04 0.63 1 1358.6%
48 Metabolon Inc., United States of America (USA) 0.36 0.60 5 62.0%
49 Bruker Corporation, United States of America (USA) 0.29 0.60 5 100.2%
50 Dow AgroSciences, United States of America (USA) 1.20 0.59 2 -52.5%

Footnote

Each year, the Nature Index publishes tables based on counts of high-quality research outputs in the previous calendar year. Users please note:

  1. The data behind the tables are based on a relatively small proportion of total research papers, they cover the natural sciences only and outputs are non-normalized (that is, they don’t reflect the size of the country or institution, or its overall research output).
  2. The Nature Index is one indicator of institutional research performance. The metrics of Count and Share used to order Nature Index listings are based on an institution’s or country’s publication output in 82 natural-science journals through 2022, in 2023 64 health-science journals were added to the Index. The 146 journals in the Nature Index were selected on reputation by an independent panel of leading scientists in their fields.
  3. Nature Index recognizes that many other factors must be taken into account when considering research quality and institutional performance; Nature Index metrics alone should not be used to assess institutions or individuals.
  4. Nature Index data and methods are transparent and available under a creative commons licence at nature.com/nature-index/.
  5. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The Nature Index database undergoes regular updating, corrections, adjustment of institutional hierarchies, and removal of retracted papers and thus the live website can differ from the frozen annual tables.

*The change in adjusted Share accounts for the small annual variation in the total number of articles in Nature Index journals. Share values have been adjusted to 2022 levels to calculate the percentage change. For more information on the adjustment, please see the Adjusted metric explainer.